The fecal mycobiome in patients with Irritable Bowel Syndrome

Abstract Alterations of the gut microbiota have been reported in various gastrointestinal disorders, but knowledge of the mycobiome is limited. We investigated the gut mycobiome of 80 patients with Irritable Bowel Syndrome (IBS) in comparison with 64 control subjects. The fungal-specific internal tr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. Das, E. O’Herlihy, F. Shanahan, P. W. O’Toole, I. B. Jeffery
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/998ef20184214f3d97b4d2f475745f4c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:998ef20184214f3d97b4d2f475745f4c
record_format	dspace
spelling	oai:doaj.org-article:998ef20184214f3d97b4d2f475745f4c2021-12-02T15:12:52ZThe fecal mycobiome in patients with Irritable Bowel Syndrome10.1038/s41598-020-79478-62045-2322https://doaj.org/article/998ef20184214f3d97b4d2f475745f4c2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-79478-6https://doaj.org/toc/2045-2322Abstract Alterations of the gut microbiota have been reported in various gastrointestinal disorders, but knowledge of the mycobiome is limited. We investigated the gut mycobiome of 80 patients with Irritable Bowel Syndrome (IBS) in comparison with 64 control subjects. The fungal-specific internal transcribed spacer 1 (ITS-1) amplicon was sequenced, and mycobiome zero-radius operational taxonomic units (zOTUs) were defined representing known and unknown species and strains. The fungal community was sparse and individual-specific in all (both IBS and control) subjects. Although beta-diversity differed significantly between IBS and controls, no difference was found among clinical subtypes of IBS or in comparison with the mycobiome of subjects with bile acid malabsorption (BAM), a condition which may overlap with IBS with diarrhoea. The mycobiome alterations co-varied significantly with the bacteriome and metabolome but were not linked with dietary habits. As a putative biomarker of IBS, the predictive power of the fecal mycobiome in machine learning models was significantly better than random but insufficient for clinical diagnosis. The mycobiome presents limited therapeutic and diagnostic potential for IBS, despite co-variation with bacterial components which do offer such potential.A. DasE. O’HerlihyF. ShanahanP. W. O’TooleI. B. JefferyNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q A. Das E. O’Herlihy F. Shanahan P. W. O’Toole I. B. Jeffery The fecal mycobiome in patients with Irritable Bowel Syndrome
description	Abstract Alterations of the gut microbiota have been reported in various gastrointestinal disorders, but knowledge of the mycobiome is limited. We investigated the gut mycobiome of 80 patients with Irritable Bowel Syndrome (IBS) in comparison with 64 control subjects. The fungal-specific internal transcribed spacer 1 (ITS-1) amplicon was sequenced, and mycobiome zero-radius operational taxonomic units (zOTUs) were defined representing known and unknown species and strains. The fungal community was sparse and individual-specific in all (both IBS and control) subjects. Although beta-diversity differed significantly between IBS and controls, no difference was found among clinical subtypes of IBS or in comparison with the mycobiome of subjects with bile acid malabsorption (BAM), a condition which may overlap with IBS with diarrhoea. The mycobiome alterations co-varied significantly with the bacteriome and metabolome but were not linked with dietary habits. As a putative biomarker of IBS, the predictive power of the fecal mycobiome in machine learning models was significantly better than random but insufficient for clinical diagnosis. The mycobiome presents limited therapeutic and diagnostic potential for IBS, despite co-variation with bacterial components which do offer such potential.
format	article
author	A. Das E. O’Herlihy F. Shanahan P. W. O’Toole I. B. Jeffery
author_facet	A. Das E. O’Herlihy F. Shanahan P. W. O’Toole I. B. Jeffery
author_sort	A. Das
title	The fecal mycobiome in patients with Irritable Bowel Syndrome
title_short	The fecal mycobiome in patients with Irritable Bowel Syndrome
title_full	The fecal mycobiome in patients with Irritable Bowel Syndrome
title_fullStr	The fecal mycobiome in patients with Irritable Bowel Syndrome
title_full_unstemmed	The fecal mycobiome in patients with Irritable Bowel Syndrome
title_sort	fecal mycobiome in patients with irritable bowel syndrome
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/998ef20184214f3d97b4d2f475745f4c
work_keys_str_mv	AT adas thefecalmycobiomeinpatientswithirritablebowelsyndrome AT eoherlihy thefecalmycobiomeinpatientswithirritablebowelsyndrome AT fshanahan thefecalmycobiomeinpatientswithirritablebowelsyndrome AT pwotoole thefecalmycobiomeinpatientswithirritablebowelsyndrome AT ibjeffery thefecalmycobiomeinpatientswithirritablebowelsyndrome AT adas fecalmycobiomeinpatientswithirritablebowelsyndrome AT eoherlihy fecalmycobiomeinpatientswithirritablebowelsyndrome AT fshanahan fecalmycobiomeinpatientswithirritablebowelsyndrome AT pwotoole fecalmycobiomeinpatientswithirritablebowelsyndrome AT ibjeffery fecalmycobiomeinpatientswithirritablebowelsyndrome
_version_	1718387646391123968

The fecal mycobiome in patients with Irritable Bowel Syndrome

Ejemplares similares